Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinical data on ARC-520, its RNAi therapeutic candidate for …
Arrowhead Research Corp On September 24, 2015 shares of Arrowhead Research Corp (NASDAQ:ARWR) were up as much as 20% after announcing positive phase …
Keryx Biopharmaceuticals (NASDAQ:KERX) rose more than 12% in pre-market trading up to $4.40 after this morning’s announcement that the company received approval in Europe …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has nominated ARC-HIF2 as its first therapeutic candidate delivered …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced that it received regulatory permission in the United Kingdom and New …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosed the first patient in Part B of a …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced that its Clinical Trial Application for ARC-520, its clinical candidate for …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced the United States Food and Drug Administration (FDA) has granted ARC-AAT …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 second quarter ended March 31, …
